Mazindol
As of the edition of 20 October 2026, Mazindol is a small molecule: marketed, first approved in 1982 (US); acts on SLC6A2, SLC6A3 and SLC6A4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Mazanor
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Novartis; 2 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Mental health; Nervous system; Chemically induced
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Mazindol.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 4 |